This Week in Cardiology

ARB recalls, bystander compression-only CPR, renal denervation for hypertension, LDL cholesterol targets, and pre-op frailty are the topics discussed in this week’s podcast.

Catheter ablation for atrial fibrillation, eggs, booze, and anti-thrombotic agents for double vs triple therapy in patients with ACS and AF are discussed in this week’s podcast.

From ACC.19 and EHRA: The Apple Heart study, TAVR for low-surgical-risk AS, preventing cardiac device infections, COACT, VF arrest, and AF cardioversion are discussed in this week's podcast.

Obesity paradox studies and collider bias, the ISCHEMIA trial baseline findings, expanded indications for the MIitraClip, and an ACC preview are covered in this week’s podcast.

N of 1 hypertension trials, heart failure readmissions and HRRP, insulin, CTA vs functional stress testing, and the ongoing paclitaxel PAD controversy are discussed in this week’s podcast.

Lead extraction, AF triggers, cognitive decline and CV risk factors, low-value care, and secondary prevention in the real world are discussed in this week’s podcast.

Factor Xa reversal agent Andexa, PTSD, gender transition hormones and CVD, primary care physician shortage, and a commentary from a young interventional cardiologist are discussed this week.

The cost of cardiac care, statin adherence and mortality, syncope, ultra-processed food, and heart failure survival are discussed in this week's podcast.

Statins in the elderly, donor hearts and the opioid crisis, Impella, coronary calcium in exercisers, and the plateau in heart disease deaths are discussed in this week’s podcast.

New guidelines for atrial fibrillation, PFO closure for stroke prevention, fried chicken, skipping breakfast and e-cigarettes are discussed in this week’s podcast.

Aspirin for primary prevention, alcohol and Afib, high-sensitivity troponin, and women in interventional cardiology are discussed in this week’s podcast.

Burnout, aspiration thrombectomy, fish intake, insurance coverage, and the gout drug febuxostat are discussed in this week’s podcast.

Appropriate use criteria for imaging, HRRP efficacy, medical marijuana, radiation exposure in the cath lab, and hormone therapy are the topics discussed this week’s podcast.

The cost of treating high blood pressure, heart-failure readmission policies, abdominal fat, low flow/low gradient aortic stenosis and hypertensive disorders of pregnancy are discussed this week.

Dr John Mandrola discusses upcoding for PCI, hypertension, a pacing lead issue, a PAD trial discovery, and an FDA warning on fluoroquinolones in this week’s podcast.

Carotid stents, more stem-cell retractions, AHA statement on statin safety, flu vaccine rules, medication errors, veterans care, and wasteful NIH research on golfing are discussed in this week’s podc…

Measures of hospital quality, statin under- or over-use, Botox for AF, smoking cessation and translating trial evidence to clinical practice are discussed in this week’s podcast.

TAVR vs surgery for high-risk aortic stenosis, conflicts of interest for physicians and societies, spin in the CV literature, and low-carb diets are discussed in this week’s podcast.

The top 5 studies from the recent American Heart Association meeting and the new cholesterol guidelines are discussed in this week’s podcast.

ODYSSEY PCSK9 inhibitor trial in print, new bradycardia guidelines, echocardiography, and an AHA preview are the topics discussed in this week’s podcast.